Accuray (NASDAQ: ARAY) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its competitors? We will compare Accuray to related companies based on the strength of its dividends, valuation, institutional ownership, risk, earnings, profitability and analyst recommendations.
Risk & Volatility
Accuray has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Accuray’s competitors have a beta of 0.89, suggesting that their average share price is 11% less volatile than the S&P 500.
This table compares Accuray and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Accuray and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Accuray Competitors||$2.02 billion||$430.74 million||-66.50|
Accuray’s competitors have higher revenue and earnings than Accuray. Accuray is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
76.7% of Accuray shares are held by institutional investors. Comparatively, 51.0% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 3.9% of Accuray shares are held by company insiders. Comparatively, 18.6% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This is a summary of current recommendations for Accuray and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Accuray presently has a consensus target price of $6.00, suggesting a potential upside of 42.86%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 5.65%. Given Accuray’s higher probable upside, research analysts clearly believe Accuray is more favorable than its competitors.
Accuray competitors beat Accuray on 7 of the 12 factors compared.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.
Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.